1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
P-3074 effectively blocks scalp DHT better than oral finasteride.
21 citations
,
January 2005 in “Pediatric Dermatology” An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.
15 citations
,
August 2002 in “British Journal of Ophthalmology” Intralesional cidofovir might be a viable alternative treatment for certain conditions.
1 citations
,
May 2021 in “Journal of the Endocrine Society” A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
15 citations
,
October 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia” 96 citations
,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
September 2025 in “The health sciences AUS.” Intralesional triamcinolone acetonide effectively treats acne keloidalis nuchae with minimal side effects.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
January 2024 in “Acta dermato-venereologica”
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Low-intensity ultrasound may protect hair follicles from damage caused by a common chemotherapy drug.
19 citations
,
November 2016 in “Dermatology and therapy” Stopping the medication infliximab and starting new treatments helped a woman's hair grow back and improved her scalp condition.
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
August 2016 in “Journal of Investigative Dermatology”
6 citations
,
July 2015 in “European Journal of Dermatology” Stopping methotrexate might reverse lymphoma-like conditions in some patients.
3 citations
,
November 2021 in “Frontiers in medicine” Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.